Early Detection of Ovarian Cancer with Transvaginal Microbubble Sonography: Current and Potential ApplicationsArthur C Fleischer*
Department of Radiology, Obstetrics and Gynecology, Vanderbilt Medical Center, USA
- *Corresponding Author:
- Arthur C Fleischer
Cornelius Vanderbilt Chair Professor, Department of Radiology
Obstetrics and Gynecology, Vanderbilt Medical Center, Nashville, TN 37232, USA
E-mail: [email protected]
Received date: Jun 28, 2016; Accepted date: Jul 09, 2016; Published date: Jul 15, 2016
Citation: Fleischer AC (2016) Early Detection of Ovarian Cancer with Transvaginal Microbubble Sonography: Current and Potential Applications. Trends Gynecol Oncol 1:106. doi:10.4172/ctgo.1000106
Copyright: © 2016 Fleischer AC. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Contrast Enhanced microbubble Transvaginal Sonography (CE-TVS) can distinguish benign and malignant ovarian tumors. Initial results from several medical centers around the world have indicated that there are unique enhancement patterns in ovarian neoplasms. Challenges to the implementation of CE-TVS remain since some aggressive ovarian tumors (type 2) that arise in the tubal epithelium and metastasize without producing a clinically detectable mass may be difficult to detect. This is being addressed through the use of labelled microbubbles which can detect rapidly growing tumor vessels. As shown in an avian model, labelled microbubbles can be used to detect neoplastic vessels associated with tumor neoangiogenesis. This has been achieved in vitro by fabrication of microbubble that have antibody attached to the lipid coat of a microbubble. In this manner, microscopic tumors that arise in the tubal epithelium might be detected in patients. This short communication describes the potential for contrast enhanced sonography to provide a means for early detection of ovarian cancer.